Vivesto is a Swedish drug development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential.

The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.

Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE).

Press releases

All press releases

Interim Report Q2 2025 (in Swedish)

Vivesto published its Q2 report for 2025 on August 12, 2025, at 08.00 am CEST.

Calendar

All events

The Share

Follow the share